HDL metabolism in context: looking on the bright side

Area of Science:

• Cardiovascular Medicine
• Lipid Metabolism
• Metabolic Syndrome Research

Background:

• High-density lipoprotein (HDL) cholesterol levels are traditionally linked to cardiovascular disease (CVD) risk.
• The role of HDL functionality and kinetics in metabolic syndrome requires further elucidation.
• Current understanding of HDL metabolism offers potential therapeutic targets for CVD prevention.

Purpose of the Study:

• To review recent data on HDL metabolism, functionality, and kinetics in relation to cardiovascular disease.
• To explore the implications of HDL apolipoproteins (apoA-I, apoA-II) as CVD predictors.
• To assess the impact of metabolic syndrome on HDL transport and the efficacy of related therapies.

Main Methods:

• Review of current scientific literature on HDL metabolism and CVD.
• Analysis of data concerning HDL apolipoproteins (apoA-I, apoA-II) and their predictive value.
• Evaluation of clinical trial outcomes, such as torcetrapib, related to HDL modulation.
• Assessment of factors influencing HDL catabolism in metabolic syndrome.
• Review of therapeutic interventions affecting HDL kinetics.

Main Results:

• HDL-apoA-I and apoA-II may be superior CVD predictors compared to HDL-cholesterol.
• Torcetrapib, an cholesteryl ester transfer protein inhibitor, showed no cardiovascular benefit, with unclear reasons for failure.
• Metabolic syndrome accelerates HDL particle catabolism due to factors like hepatic apoB/apoC-III secretion, hepatic steatosis, and low adiponectin.
• Weight loss, fish oils, high-dose statins, and fibrates may improve HDL transport in metabolic syndrome; fenofibrate uniquely increases apoA-I production.

Conclusions:

• Therapeutic strategies should prioritize increasing HDL-apoA-I and apoA-II over solely raising HDL-cholesterol.
• Investigating HDL functionality is crucial, especially in patients with metabolic syndrome.
• Current methods for assessing reverse cholesterol transport are limited; new approaches are needed.
• Optimizing HDL-raising therapies in metabolic syndrome involves enhancing HDL transport and concentration while maintaining or accelerating catabolism.